Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
ApexOnco Front Page
Recent articles
28 October 2024
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
21 October 2024
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
17 October 2024
The French group takes a shot at Perspective with its second bet on Orano Med.
16 October 2024
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
16 October 2024
The Hutchmed-originated savolitinib moves towards its first US approval.
15 October 2024
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
Recent Quick take
- 18 October 2024
- 18 October 2024
- 16 October 2024
- 15 October 2024
- 14 October 2024
- 14 October 2024
- 14 October 2024
- 14 October 2024
- 10 October 2024
- 10 October 2024